<DOC>
	<DOCNO>NCT02352311</DOCNO>
	<brief_summary>This randomize , open-label , single-dose , 2-treatment , 2-way , 2-period crossover study evaluate safety pharmacokinetic characteristic DKF-313 ( dutasteride tadalafil ) healthy male volunteer .</brief_summary>
	<brief_title>Safety Pharmacokinetic Characteristics DKF-313</brief_title>
	<detailed_description>This study conduct evaluate pharmacokinetics DKF-313 ( dutasteride tadalafil ) compare concomitant administration AVODART CIALIS healthy male volunteer .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>1 . Age 19 29 year 2 . BMI 17.5 30.5 kg/m2 body weight 55 kg 3 . No congenital chronic disease within 3 year , disease symptom find 4 . Eligible accord laboratory result hematology , blood chemistry urinalysis ECG 5 . Voluntarily sign informed consent form 6 . Willing participate study 1 . Clinically significant disorder blood , kidney , endocrine , respiratory system , gastrointestinal system , urology , cardiovascular system , liver , psychiatry , neurology allergy 2 . Gastrointestinal disease surgery may affect absorption investigational product 3 . ALT AST &gt; 2xULN 4 . Excessive alcohol consumption ( &gt; 210 g/week ) within 6 month 5 . Participated administer investigational product clinical trial within 2 month 6 . SBP ≤ 100 mmHg ≥ 150 mmHg DBP ≤ 60 mmHg ≥ 100 mmHg 7 . History positive result serious alcohol drug abuse within 1 year 8 . Drugs induce inhibit drug metabolism within 1 month 9 . Smoked 10 cigarette day 10 . Prescribed drug overthe counter drug within 10 day 11 . Donated whole blood within 2 month apheresis within 1 month 12 . Severe acute/chronic medical mental condition lab abnormality may increase risk interfere interpretation study result 13 . Hypersensitivity tadalafil phosphodiesterase type 5 inhibitor , dutasteride 5α reductase inhibitor , drug include aspirin , antibiotic , etc . 14 . Galactose intolerance , fructose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption 15 . CYP3A4 inhibitor CYP3A4 inducer within 2 week 16 . Myocardial infarction within 90 day 17 . Unstable angina angina sexual intercourse 18 . Heart failure ( New York Heart Association Class 2 high ) within 6 month 19 . Uncontrolled arrhythmias 20 . Stroke within 6 month 21 . Inherited retinal degeneration include retinitis pigmentosa 22 . Vision loss one eye due nonarteritic anterior ischemic optic neuropathy ( NAION ) 23 . Plans donate blood least 6 month final dose investigational product 24 . Unwilling comply lifestyle guideline protocol 25 . Not eligible due reason investigator 's discretion</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>